Biocon shares jump 6% as Mylan exits via block deals

Biocon shares rose more than 6% to Rs 436.15 on Tuesday, marking the stock’s highest level since May 29 and putting it on track for its best single-day gain since January. The rally was driven by heavy block trading activity in the early session. Nearly nine crore shares changed hands across two separate block deals, a volume that closely aligns with the 5.64% equity stake that Mylan targeted for divestment.

Mylan, a subsidiary of the global healthcare company Viatris, fixed a floor price of Rs 378.50 per share for the transaction. This pricing represented an almost 8% discount to Biocon’s previous closing price of Rs 410.95. Citigroup Global Markets India and Jefferies India were appointed as the joint bookrunners and brokers for the offering. While the seller in the morning block transactions has not been formally confirmed, the volume of shares traded indicates the Mylan exit is effectively underway.

The clearance of this block is a significant development for Biocon’s equity story. Large stake sales by corporate investors often create an overhang, weighing on a stock's performance due to the anticipated supply of shares hitting the open market. The fact that the stock surged past the block deal floor price suggests strong institutional demand to absorb the entire tranche.

This demand stands in stark contrast to broader weakness across the Indian equity market. A wider market selloff saw the Sensex fall 500 points and the Nifty slip below 24,100 amid an escalating US-Iran conflict. Biocon’s ability to decouple from this selling pressure underscores the stock-specific nature of the block trade and the appetite for the biopharmaceutical firm's shares at a discounted entry point.

Mylan’s departure will reshape Biocon’s shareholding structure. According to National Stock Exchange data for the last financial year, the Viatris unit held a 5.64% stake. Founder and promoter Kiran Mazumdar Shaw remains the controlling shareholder with an approximately 30% holding. Glentec International is the next largest declared shareholder, holding around 15% of the outstanding equity.

The stock has now accumulated a gain of around 7% over the past week and roughly 4% over the past month. The successful placement of the Mylan stake removes a key uncertainty, leaving the stock's future trajectory dependent on the company’s operational performance rather than structural selling pressure.